Phase 1-2 Study of the Safety Pharmacokinetics and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas

Brief description of study

The purpose of the study is to determine the safety of ASTX660 and to see if this drug may interfere with the function of cancer cells continuing to produce proteins. One of the ways that cancer cells continue to grow is by producing proteins called "Inhibitors of apoptosis proteins (IAPs)" that block the normal cell death pathway of human cells. ASTX660 may lead to improved efficacy due to the more effective activation of apoptosis defined by the death of cells which occurs as a normal and controlled part of an organism's growth or development. This study is experimental because the study drug ASTX660 has not been approved by the Food and Drug Administration (FDA) and other regulatory authorities for the treatment of any disease, including cancer. The FDA has given its permission to test this agent in the current trial.

Clinical Study Identifier: s19-01110 Identifier: NCT02503423

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.